July 28, 2026
Claris Biotherapeutics
Claris Biotherapeutics secures $118M Series B funding to advance CSB-001, a pharmacologic therapy for limbal stem cell deficiency.
- Round
- Series B
- Amount raised
- $118M
- Lead investor
- —
- Industry
- Biotechnology Research
- Headquarters
- United States
- Employees
- 2-10 employees
- Website
- clarisbio.com
- View profile →
Source: AllSci